Transmedics Group Stock Earnings Reports

TransMedics reported a solid start to 2026 with 1Q revenue of $174M (up ~21% YoY, ~8% sequential), driven by strong liver performance, continued heart progress and growing logistics (NOP) revenue. Adjusted operating profit was ~$18.1M (10% adjusted operating margin). The company ended the quarter with ~$462M in cash. Management reiterated full-year 2026 revenue guidance of $727M–$757M (20%–25% growth). TransMedics is investing heavily across several strategic growth initiatives in 2026—funding ENHANCE and DENOVO cardiothoracic clinical programs, completing the Gen 3.0 OCS Kidney development (IDE target early 2027), upgrading heart/lung/liver systems to Gen 3.0, launching CHOPS (a regulated controlled hypothermic preservation device) to serve as the control arm in trials and pursue a separate 510(k) commercial pathway, and expanding the NOP logistics model into Europe (including an investment/partnership with PAD Aviation). Management warned that near-term financials will reflect deliberate, front-loaded investments (R&D, NOP expansion, HQ and ERP) that pressure margins in the short term but are intended to drive long-term market expansion and profitability. Key operational notes: OUS revenue remains early-stage but growing; NOP U.S. fleet to remain at 22 aircraft with efforts to maximize utilization; CHOPS IDE supplement to be filed in coming weeks with expectation to implement in early Q3 2026; ENHANCE Part A enrollment is tracking ahead, Part B and DENOVO impacted earlier by competitive reaction but expected to accelerate once CHOPS is approved as the control arm. Management expects gross margin to normalize toward ~60% long-term, though near-term pressure is expected due to inventory/supply chain positioning and investments.